BeStock  
Stocks › Biotechnology › HRMY

Harmony Biosciences HRMY

US equityMarket cap rank #2704Biotechnology
$32.59 −$0.39 (-1.18%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $32.59 0.00%
Open$32.68
Prev close$32.98
Day range$32.51 – $33.43
Volume582.6K
Market cap$1.91B
P/E (TTM)10.8
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

HRMY at a glance

Harmony Biosciences stock (HRMY) sits at $32.59, down 1.18% today. The business is worth $1.91B in the market, good for #2704 of 3753 on our coverage list.

Over the past 52 weeks it has traded between $25.90 and $43.49, so it sits 25.1% below the top of that range. Holders are behind 5.0% over twelve months, and down 15.4% across the last three months.

On the chart it has slipped under both the 50-day ($37.77) and 200-day ($34.47) moving averages; RSI is 32, and the last 30 sessions moved at roughly 43% annualized volatility.

Revenue for the quarter ended Sep 2026 was $268.92M, up 12.3% from a year earlier, with $48.20M of net profit (a 18.1% margin).

Valuation works out to 10.8 times trailing earnings, 47% below its five-year average of 20.4. The median for its industry group is 17.1.

8 analysts follow the stock and the average call is "buy". The mean target, $47.50, sits 45.8% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

Key statistics

Bid / Ask$30.51 / $34.50
Average price today$32.83
Volume582.6KAvg (90d) 953.3K
Turnover$19.13M
Turnover rate1.11%of shares outstanding
Volume ratio0.82vs. recent average pace
Day amplitude2.77%
Market cap$1.91B
Float market cap$1.71B
Shares outstanding52.58M
EPS (TTM)$2.71
P/E (TTM)10.79
P/B1.78
Book value / share$18.26
Earnings yield9.27%
Net profit (TTM)$159.14M
Net assets$1.07B
30-day volatility42.9%annualized
Avg daily range (ATR)4.66%of price, 14 days
Max drawdown (1y)-34.5%-24.0% from 1y peak

Quote as of Nov 20, 2026 8:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.

BeStock Grade

B
BeStock Grade

Composite of 3 factors below, ranked against the 3734 U.S. stocks BeStock covers.

B
Valuation

Cheaper than usual on its own 5-year P/E history scores higher.

C
Momentum

Trading closer to its 52-week high than most peers scores higher.

B
Wall Street

8 analysts, consensus Buy.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

Six-factor research snapshot

Overall percentile: 97.9 · 2026-11-22 14:27 UTC. Higher values indicate a stronger relative ranking.

FactorPercentile
Valuation89.9
Growth74.6
Profitability91.6
Momentum48.2
Financial health91.7
Analyst view53.2

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Analyst price target (avg)$47.50+45.8% vs. current price
Consensus ratingBuy8 analysts covering
Morningstar fair value$35.60Price is below fair value

Wall Street’s average 12-month target is $47.50, 45.8% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $35.60, so shares trade 8.5% below that estimate. On earnings multiple, it sits in the 17th percentile of its own five-year valuation range (cheaper than usual).

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
-1.2%
1 week
-3.5%
1 month
-9.5%
3 months
-15.4%
6 months
+8.1%
Year to date
-12.9%
1 year
-5.0%
Day range
$32.51$33.43
52-week range
$25.90$43.49

Technical signals

Full technicals →
Trend readStrong downtrend

1 bullish · 6 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average-6.8%Bearish
Price vs 50-day average-13.7%Bearish
Price vs 200-day average-5.4%Bearish
50-day vs 200-day50d above 200dBullish
RSI (14)32.5Bearish
MACD (12,26,9)-1.44Bearish
Bollinger band position24%Bearish

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

How HRMY ranks on BeStock

Market value#2693 of 3734
P/E (cheapest = 1)#689 of 2917
Closeness to 52-week high#1838 of 3724
Dollar volume today#2036 of 3734

Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

Set against the peer table: at 10.8x earnings, HRMY looks cheap against the market, and trades 37% below the 17.1x median among Biotechnology names. The two comparisons do not always agree.

HRMY is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.

Strategy Backtest

Pick a strategy above and run the backtest to see its simulated performance on HRMY.

Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.

Community Sentiment on HRMY

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

HRMY stock: common questions

Where is HRMY trading right now?

$32.59 is the latest print for HRMY, a move of -1.18% against yesterday's close of $32.98. Today's low and high so far: $32.51 and $33.43.

How big is Harmony Biosciences?

Equity value comes to $1.91B at the current price. By that measure it is number 2704 of the 3753 names in our coverage.

What multiple of earnings does HRMY sell for?

Buyers pay 10.8 times the last twelve months of profit (EPS $2.71). Averaged over five years the multiple has been 20.4, and today's level ranks in the 17th percentile of its own history.

Is HRMY near its 52-week high or low?

The year's floor is $25.90 and the ceiling $43.49. Shares are 25.1% away from that ceiling.

Does Harmony Biosciences pay a dividend?

Our data shows no dividend paid by Harmony Biosciences over the trailing twelve months.

Is HRMY rated a buy by Wall Street?

Of 8 analysts, 63% say buy, 25% hold and 13% sell. Price targets average $47.50, with the most cautious at $30.00 and the most optimistic at $60.00.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on HRMY.

Sign in to join the discussion.

Scroll to Top